<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778592</url>
  </required_header>
  <id_info>
    <org_study_id>ETX-018810-201</org_study_id>
    <nct_id>NCT04778592</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ETX 018810 in Subjects With Lumbosacral Radicular Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Lumbosacral Radicular Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eliem Therapeutics (UK) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eliem Therapeutics (UK) Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy&#xD;
      and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo Controlled, Parallel-group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind Placebo Controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 4 in the weekly average of the daily pain score</measure>
    <time_frame>Week 4</time_frame>
    <description>Efficacy of ETX 018810 for the treatment of lumbosacral radicular pain will be assessed from change from baseline to Week 4 in the weekly average of the daily pain score on the 11 point Pain Intensity Numerical Rating Scale (PI NRS) from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Lumbosacral Radiculopathy</condition>
  <arm_group>
    <arm_group_label>ETX-018810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: ETX-018810 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETX-018810</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>ETX-018810</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has pain consistent with a diagnosis of chronic lumbosacral radiculopathy&#xD;
             due to injury of the lumbosacral nerve root(s)&#xD;
&#xD;
          -  The subject reports at least moderate pain intensity at screening.&#xD;
&#xD;
          -  The subject's onset of leg pain due to LSRP is at least 3 months&#xD;
&#xD;
          -  The subject has a magnetic resonance imaging (MRI) scan that is normal or shows&#xD;
             incidental lesions&#xD;
&#xD;
          -  The subject has a calculated creatinine clearance â‰¥30 mL/min&#xD;
&#xD;
          -  The subject has clinical laboratory values within normal limits or abnormal values&#xD;
             that the investigator deems not clinically significant.&#xD;
&#xD;
          -  body mass index (BMI) &lt;40 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has previously undergone back surgery&#xD;
&#xD;
          -  The subject is unable to reliably delineate or assess pain by anatomical&#xD;
             location/distribution on a body map.&#xD;
&#xD;
          -  The subject has a history of peripheral neuropathy, evidence of peripheral neuropathy,&#xD;
             or evidence of mononeuropathy in the same limb of LSRP.&#xD;
&#xD;
          -  The subject has pain due to infection/abscess, hematoma, or malignancy or other pain&#xD;
             that may interfere with the assessment of LSRP in the legs.&#xD;
&#xD;
          -  The subject has clinically significant and/or unstable renal, hepatic, hematologic,&#xD;
             endocrine, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular&#xD;
             disease that would compromise participation in the study&#xD;
&#xD;
          -  The subject has any neurological disease that could interfere with participation in&#xD;
             the study (e.g., Huntington's disease, Parkinson's disease, Alzheimer's disease,&#xD;
             multiple sclerosis, seizures, epilepsy, stroke).&#xD;
&#xD;
          -  The subject has a history or current diagnosis of major psychiatric disorder(s)&#xD;
&#xD;
          -  The subject has a has a history of substance abuse or dependence&#xD;
&#xD;
          -  The subject has clinically significant abnormal electrocardiogram (ECG) findings&#xD;
&#xD;
          -  The subject has received nerve blocks and/or steroid injections for LSRP within the 3&#xD;
             months before screening&#xD;
&#xD;
          -  The subject is unwilling or unable to discontinue current medications for LSRP,&#xD;
             including topical agents.&#xD;
&#xD;
          -  The subject is unable to refrain from using prohibited meds during the study,&#xD;
             including: NSAID, antiepileptic drugs, steroids, cannabinoids, or major opioids,&#xD;
             antidepressants, muscle relaxants, tramadol, or tapentadol.&#xD;
&#xD;
          -  The subject has used prohibited nonpharmacologic therapies, including acupuncture,&#xD;
             transcutaneous electrical nerve stimulation, within 30 days the study.&#xD;
&#xD;
          -  The subject is currently participating in another or the same clinical study or&#xD;
             participated in another clinical study within 3 months before screening&#xD;
&#xD;
          -  The subject is pregnant or lactating or not practicing adequate birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head Clinical Operations</last_name>
    <phone>877-834-0490</phone>
    <email>studyinfo@eliemtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Delta Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-848-8900</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

